Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Aduro Biotech Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies for the Treatment of Ovarian Cancer

GlobeNewswire September 9, 2015

Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody

Business Wire September 2, 2015

Incyte to Present at Upcoming Investor Conferences

Business Wire September 1, 2015

Incyte Named 7th Most Innovative Company in the World by Forbes Magazine

Business Wire August 21, 2015

Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

Business Wire August 4, 2015

Incyte to Report Second Quarter Financial Results on August 4

Business Wire July 14, 2015

Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance

Business Wire July 7, 2015

Incyte Announces Organizational and Management Changes to Drive Future Global Expansion

Business Wire June 19, 2015

Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis

PR Newswire June 10, 2015

Advaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incyte's epacadostat for the Treatment of HPV-Associated Early Stage Cervical Cancer

PR Newswire June 1, 2015

Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data

PR Newswire May 28, 2015

Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings

Business Wire May 27, 2015

Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

Business Wire April 30, 2015

Incyte to Present at Upcoming Investor Conferences

Business Wire April 23, 2015

Incyte to Report First Quarter Financial Results on April 30

Business Wire April 14, 2015

Incyte to Establish European Headquarters in Geneva, Switzerland

Business Wire April 14, 2015

Jakavi® (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera

Business Wire March 17, 2015

Incyte Appoints Steven H. Stein, MD as Chief Medical Officer

Business Wire March 2, 2015

Incyte Sponsors First Observational Study Designed to Understand the Impact of Polycythemia Vera - a Rare, Progressive Blood Cancer

Business Wire February 26, 2015

Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3 Study

PR Newswire February 23, 2015